Certara, Inc. (CERT)
After hours:
| Previous Close | 23.86 |
| Open | 24.14 |
| Bid | 0.00 x 800 |
| Ask | 0.00 x 800 |
| Day's Range | 23.58 - 24.14 |
| 52 Week Range | 10.60 - 24.83 |
| Volume | |
| Avg. Volume | 1,310,895 |
| Market Cap | 3.805B |
| Beta (5Y Monthly) | 1.45 |
| PE Ratio (TTM) | 264.44 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
A.I. Coming to Certara’s D360 Scientific Informatics Software
New deep learning capabilities will provide data and insight to inform property prioritization, novel structure design and literature-based analyses.PRINCETON, N.J., March 09, 2023 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, is adding deep learning capabilities to D360, a leading scientific informatics software platform. The addition of novel A.I. will enable discovery scientists to integrate multiple structured and unstructured data sources and substantia
- GlobeNewswire
Certara announces the release of Simcyp™ PBPK Simulator Version 22, expanding ability to simulate untested scenarios for new patient and therapeutic types
Simcyp Simulator has been utilized to inform more than 300 label claims for 90+ novel drugs in lieu of conducting clinical studiesPRINCETON, N.J., March 07, 2023 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced the release of Simcyp Simulator Version 22, which includes new capabilities and updated features to the Company’s population-based modeling and simulation platform. The Simcyp Simulator is the pharmaceutical industry’s most sophisticated
- GlobeNewswire
Certara Reports Fourth Quarter and Full Year 2022 Financial Results
Annual Revenue Grows 17% on a Reported Basis and 20% at Constant CurrencyPRINCETON, N.J., March 01, 2023 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today reported its financial results for the fourth quarter and full year of 2022 and issued guidance for 2023. Fourth Quarter Highlights: Revenue was $86.6 million, compared to $75.3 million in the fourth quarter of 2021, representing growth of 15% over the fourth quarter of 2021 on a reported basis and 18% a
